Intercept Pharmaceuticals (ICPT) Upgraded to “Hold” by BidaskClub

Intercept Pharmaceuticals (NASDAQ:ICPT) was upgraded by equities research analysts at BidaskClub from a “sell” rating to a “hold” rating in a report issued on Friday, BidAskClub reports.

A number of other brokerages have also recently commented on ICPT. Raymond James reiterated a “buy” rating on shares of Intercept Pharmaceuticals in a research note on Thursday, February 14th. Credit Suisse Group reiterated an “outperform” rating on shares of Intercept Pharmaceuticals in a research note on Tuesday, February 12th. Wedbush set a $251.00 price target on Intercept Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, March 5th. Needham & Company LLC upgraded Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $150.00 price target for the company in a research note on Thursday, January 24th. Finally, B. Riley reiterated a “buy” rating and issued a $169.00 price target (up from $155.00) on shares of Intercept Pharmaceuticals in a research note on Thursday, February 28th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and seventeen have given a buy rating to the company. Intercept Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $145.67.

Shares of ICPT opened at $88.47 on Friday. Intercept Pharmaceuticals has a 52 week low of $65.63 and a 52 week high of $133.74. The firm has a market capitalization of $2.49 billion, a PE ratio of -8.15 and a beta of 1.49. The company has a debt-to-equity ratio of 19.41, a current ratio of 3.72 and a quick ratio of 3.72.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($3.03) EPS for the quarter, missing the Zacks’ consensus estimate of ($2.57) by ($0.46). Intercept Pharmaceuticals had a negative net margin of 162.49% and a negative return on equity of 617.23%. The firm had revenue of $52.25 million during the quarter, compared to the consensus estimate of $52.15 million. During the same quarter in the previous year, the company posted ($3.22) earnings per share. The firm’s revenue was up 45.3% on a year-over-year basis. As a group, analysts expect that Intercept Pharmaceuticals will post -9.56 EPS for the current year.

In related news, Director Srinivas Akkaraju sold 23,438 shares of the stock in a transaction on Tuesday, February 19th. The stock was sold at an average price of $128.78, for a total value of $3,018,345.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider David Shapiro sold 2,000 shares of the stock in a transaction on Friday, March 1st. The shares were sold at an average price of $103.16, for a total value of $206,320.00. Following the completion of the sale, the insider now owns 42,543 shares of the company’s stock, valued at $4,388,735.88. The disclosure for this sale can be found here. Insiders sold 32,504 shares of company stock valued at $3,919,487 over the last 90 days. 4.90% of the stock is currently owned by company insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of New York Mellon Corp grew its holdings in Intercept Pharmaceuticals by 3.7% during the 3rd quarter. Bank of New York Mellon Corp now owns 93,227 shares of the biopharmaceutical company’s stock worth $11,780,000 after acquiring an additional 3,342 shares during the period. Teachers Advisors LLC grew its holdings in Intercept Pharmaceuticals by 3.0% during the 3rd quarter. Teachers Advisors LLC now owns 43,018 shares of the biopharmaceutical company’s stock worth $5,436,000 after acquiring an additional 1,254 shares during the period. Legal & General Group Plc grew its holdings in Intercept Pharmaceuticals by 30.8% during the 3rd quarter. Legal & General Group Plc now owns 8,849 shares of the biopharmaceutical company’s stock worth $1,118,000 after acquiring an additional 2,086 shares during the period. Federated Investors Inc. PA grew its holdings in Intercept Pharmaceuticals by 1,156.8% during the 3rd quarter. Federated Investors Inc. PA now owns 85,025 shares of the biopharmaceutical company’s stock worth $10,744,000 after acquiring an additional 78,260 shares during the period. Finally, Virtu Financial LLC acquired a new stake in Intercept Pharmaceuticals during the 4th quarter worth about $538,000. Institutional investors and hedge funds own 68.38% of the company’s stock.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults.

Recommended Story: Hedge Funds – Risk or Reward?

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.